Friday, October 19, 2007

Unreasonable expectations for new type 2 diabetes drugs

Physiology and clinical epidemiology give us no reason to expect that glycemic control with any drug should prevent heart attacks or strokes (macrovascular benefit). In fact, the most time tested and trusted class of oral agents for type 2 diabetes is associated with macrovascular harm. Had macrovascular benefit been the standard for approval of drugs for type 2 diabetes all along we would now have only two drugs available: metformin and pioglitazone.

Of course all this got started as a result of the Avandia bru-ha-ha. I‘ve ranted about this macrovascular issue here and elsewhere. Here’s an expert who seems to agree, commenting in a recent issue of DOC News:

But as a medical community, do we want to prove that our agents to treat type 2 diabetes improve heart attack and stroke risk before approval?

I think not.

1 comment: said...


I hope all is well with you. Healthline just published an overview of a ConsumerReports’ evaluation of treatments and medications for Type II Diabetes. This is highly valuable information as it provides diabetes patients with an understanding of which medication is right for them.

You can see the overview of the report here:

Our users have found our guide very useful, and I thought it would be a great resource for your page:

I would really appreciate if you could review our request and consider adding this very useful information to your site.

Please let me know if you have any questions.

All the best,
Maggie Danhakl • Assistant Marketing Manager
p: 415-281-3124 f: 415-281-3199

Healthline • The Power of Intelligent Health
660 Third Street, San Francisco, CA 94107 | @Healthline | @HealthlineCorp

About Us: